The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
about
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectivesGenetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapyEmerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancerCryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy.Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancerPrognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors.Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancerβ-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signalingLeptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese womenRapamycin and WYE-354 suppress human gallbladder cancer xenografts in miceSerine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancersHOTAIR Promotes Proliferation, Migration, and Invasion of Ovarian Cancer SKOV3 Cells Through Regulating PIK3R3Cancerous Inhibitor of PP2A Silencing Inhibits Proliferation and Promotes Apoptosis in Human Multiple Myeloma Cells.Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.Gene Set-Based Functionome Analysis of Pathogenesis in Epithelial Ovarian Serous Carcinoma and the Molecular Features in Different FIGO StagesCXCR2 Inhibition in Human Pluripotent Stem Cells Induces Predominant Differentiation to Mesoderm and Endoderm Through Repression of mTOR, β-Catenin, and hTERT Activities.The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.A Review of mTOR Pathway Inhibitors in Gynecologic CancerAkt isoform specific effects in ovarian cancer progression.Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options.An overview of early investigational therapies for chemoresistant ovarian cancer.Epothilone B induces apoptosis and enhances apoptotic effects of ABT-737 on human cancer cells via PI3K/AKT/mTOR pathway.Asiatic acid exerts anticancer potential in human ovarian cancer cells via suppression of PI3K/Akt/mTOR signalling.Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Prediction of therapy response in ovarian cancer: Where are we now?Preclinical study of CC223 as a potential anti-ovarian cancer agent.Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease.Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.Metabolic syndrome in rats is associated with erectile dysfunction by impairing PI3K/Akt/eNOS activity.Mangiferin induces apoptosis in human ovarian adenocarcinoma OVCAR3 cells via the regulation of Notch3.PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction.
P2860
Q26749280-4F300300-47BB-4405-89DB-3C5A3445E646Q26769604-F33D3E04-48B6-4D59-8E5E-9C4AEBB0C3ABQ26778509-DF396D12-FA48-496D-8A8F-B71B32A61AFDQ32174351-7EF74965-66DB-4AB9-8268-83BCE7E43D85Q33563929-60E3A5F6-BDA9-4A42-A001-B3092CD6E77FQ33735170-D0EAA844-BE4B-4E4F-A369-F2772BA0D23FQ33813234-4C2367B9-D4DC-4165-B5D5-1BEEEDF9DBA9Q35732942-5813E534-219B-4DA1-8200-B8F98AC04E4DQ35941337-5D7CD2AD-B139-4F6F-98EA-A9D8F40DCA01Q35992948-17589A58-EEAA-4224-A01F-D5F7FA0AFFD1Q36334776-12FA1CDA-C4C6-4E1D-8B79-A471F19D68F5Q36356253-1098A28C-AB09-43DF-940D-6477BAC2A93FQ36544718-942889D9-A4F9-4136-848E-CE15D24462CDQ36546449-2755575A-AFAC-4E84-AFC8-A4D60DE3FC67Q36572158-6DAF2FD4-920D-407A-AEF3-78B02E8088C0Q36814489-3FFC18AC-4BF0-4A6F-B7B4-8440B254BB49Q36891653-AB684B04-7A4D-48DE-8CCD-33BFEB513A47Q37022406-53C262AA-0F6A-4E53-8F4F-AFDC4B29CA67Q37050667-2889CEF6-4D91-4BF5-A043-9CE645814EBFQ37061263-646404A1-F3EB-4058-ABC4-24CD956404DAQ37631697-CAB49CA6-6A51-4906-A117-65F5CAAEF577Q37637147-6CD87F93-208C-45DE-9528-1FED468B703AQ37668889-EA17EBA5-9AEB-42AE-859D-2038478DF671Q37688855-A6C10939-CCB7-4D12-ADAD-415490E06FD4Q37696147-FA0BF105-06E9-4FBA-A490-3ACDA0ED9B10Q37710456-C65B4EA0-263E-4C50-B256-8EA6FCCD9078Q38553247-5F5B9176-DCD4-4440-8069-6800CA17E7FDQ38748411-113898C2-434D-4BBA-BFB3-06E133939EACQ38785763-5A554AED-9F58-492B-8B70-ED893B778718Q38792699-9635B8DD-79E5-425D-A362-38DA10C68BFEQ38829846-C5961F24-2500-4D84-95B3-30BD59245D9BQ39233197-8A4D79EF-0273-4ED4-B6A2-D029199724FEQ39263260-130C324C-FFBC-40BE-90A0-C712BB0F367FQ41709197-E5013981-3DB0-47B0-A5A6-E34307E6092BQ41777292-8B65D236-28DD-48BA-A2B3-681856D203FFQ42378299-81B2674D-1ECC-461F-A977-33727626FAA3Q42677598-57A96A4F-3611-4783-A8C2-569807CE9A88Q42838310-D035C980-238A-4493-9CE0-D8EB206DCF00Q43300329-8C733C59-1ABC-4C7C-9F6B-FD246919D9A3Q46319823-8B5B74B8-FD97-455F-9976-D95B67776B7B
P2860
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
@en
type
label
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
@en
prefLabel
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
@en
P2093
P1433
P1476
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
@en
P2093
Ryoko Takahashi
Seiji Mabuchi
Tomoyuki Sasano
P304
P356
10.1016/J.YGYNO.2015.02.003
P407
P577
2015-02-10T00:00:00Z